Efficient derivation of dopaminergic neurons from SOX1⁻ floor plate cells under defined culture conditions.
Li M, Zou Y, Lu Q, Tang N, Heng A, Islam I, Tong HJ, Dawe GS, Cao T
This study developed a method to efficiently create functional dopaminergic neurons from stem cells without using sonic hedgehog, which could help treat Parkinson's disease. The process relies on turning off SOX1 expression first, then guiding cells into dopamine-producing neurons that improved motor function in rats.
- SOX1-negative floor plate cells are key to making dopamine neurons
- A Shh-free method produces over 98% functional dopaminergic neurons
- Turning off SOX1 is essential for successful neuron development
- Transplanted neurons improved motor symptoms in Parkinson's model rats
- Method could lead to better stem cell therapies for Parkinson's
Methyl-Arginine Profile of Brain from Aged PINK1-KO+A53T-SNCA Mice Suggests Altered Mitochondrial Biogenesis.
Auburger G, Gispert S, Brehm N
This study in mice with two Parkinson's-related gene mutations shows that mitochondrial function is disrupted early, with key proteins involved in energy production and brain cell health being affected. The findings highlight a specific pathway involving NURR1 and other factors that may contribute to the vulnerability of dopamine-producing brain cells.
- Mitochondrial function is impaired in mice with Parkinson's gene mutations
- Proteins linked to NURR1 and dopamine neuron development are disrupted
- Early changes in energy production may explain brain cell vulnerability
- Findings point to potential targets for protecting brain cells
Regulation of differentiation flux by Notch signalling influences the number of dopaminergic neurons in the adult brain.
Trujillo-Paredes N, Valencia C, Guerrero-Flores G, Arzate DM, Baizabal JM, Guerra-Crespo M, Fuentes-Hernández A, Zea-Armenta I, Covarrubias L
Notch signaling controls how many dopaminergic neurons are made in the adult brain by regulating when and how neural precursor cells turn into neurons. When Notch signaling is reduced, precursor cells differentiate too early, leading to fewer dopaminergic neurons overall, especially in the substantia nigra—a key area affected in movement disorders.
- Notch signaling delays neuron formation to allow proper precursor expansion
- Reduced Notch leads to fewer dopaminergic neurons in the substantia nigra
- Early differentiation depletes precursor cells needed for sustained neuron production
- A feedback loop between precursors and progenitors controls neuron output
- This process may affect conditions like Parkinson’s or NR4A2-related syndromes
Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.
Wang J, Bi W, Zhao W, Varghese M, Koch RJ, Walker RH, Chandraratna RA, Sanders ME, Janesick A, Blumberg B, Ward L, Ho L, Pasinetti GM
IRX4204 is a drug that activates Nurr1, a key protein involved in protecting dopamine-producing brain cells, and can cross the blood-brain barrier to reach the brain. In animal models, it helps preserve these neurons and improves movement and brain chemistry deficits seen in Parkinson's disease.
- IRX4204 activates Nurr1, a critical protein for dopamine neuron survival.
- It crosses the blood-brain barrier and reaches effective levels in the brain.
- In rats, it reduces Parkinson’s-like symptoms and protects dopamine neurons.
- This suggests a potential treatment to slow Parkinson’s progression.
A MED13-dependent skeletal muscle gene program controls systemic glucose homeostasis and hepatic metabolism.
Amoasii L, Holland W, Sanchez-Ortiz E, Baskin KK, Pearson M, Burgess SC, Nelson BR, Bassel-Duby R, Olson EN
Skeletal muscle uses a specific gene program controlled by MED13 to regulate blood sugar and liver fat levels, improving insulin sensitivity and protecting against fatty liver, even without weight changes. This process involves the suppression of NURR1, a protein linked to NR4A2-related syndrome.
- Skeletal muscle controls liver fat via a MED13-dependent gene program
- MED13 suppresses NURR1, affecting glucose metabolism
- Improved insulin sensitivity reduces blood sugar and liver fat
- This mechanism works independently of body weight
- NURR1 is a key player in this metabolic regulation
DJ-1/PARK7, But Not Its L166P Mutant Linked to Autosomal Recessive Parkinsonism, Modulates the Transcriptional Activity of the Orphan Nuclear Receptor Nurr1 In Vitro and In Vivo.
Lu L, Zhao S, Gao G, Sun X, Zhao H, Yang H
DJ-1 helps activate Nurr1, a key protein for dopamine neuron development, by boosting its movement into the cell nucleus and its ability to turn on genes. This effect is lost when DJ-1 has the L166P mutation, which is linked to early-onset Parkinson’s disease.
- DJ-1 boosts Nurr1 activity in neurons
- L166P mutant DJ-1 fails to activate Nurr1
- The Raf/MEK/ERK pathway mediates this effect
- Nurr1 is critical for dopamine neuron health
- This reveals a new link between DJ-1 and Parkinson’s
Differential Neuronal Plasticity of Dental Pulp Stem Cells From Exfoliated Deciduous and Permanent Teeth Towards Dopaminergic Neurons.
Majumdar D, Kanafi M, Bhonde R, Gupta P, Datta I
Stem cells from adult permanent teeth (DPSCs) differentiate more effectively into dopamine-producing neurons than stem cells from baby teeth (SHED), likely due to higher levels of key signaling receptors and better response to developmental cues. This suggests DPSCs may be more useful for research or therapies targeting dopamine-related conditions.
- DPSCs outperform SHED in making dopamine neurons
- Higher SHH receptor levels in DPSCs aid differentiation
- SHED have lower baseline dopamine markers
- DPSCs release more dopamine and respond better to stimuli
- cAMP response differences may affect neuron development
Prostaglandins from Cytosolic Phospholipase A2α/Cyclooxygenase-1 Pathway and Mitogen-activated Protein Kinases Regulate Gene Expression in Candida albicans-infected Macrophages.
Yun B, Lee H, Jayaraja S, Suram S, Murphy RC, Leslie CC
Infection with Candida albicans triggers a signaling pathway in macrophages that produces prostaglandins and increases cAMP, leading to changes in gene expression that control inflammation. This pathway involves cPLA2α, COX-1, MAP kinases, and the transcription factor CREB, and it regulates key immune genes including Nr4a2, which is relevant to NR4A2-related syndrome.
- NR4A2 gene expression is boosted by prostaglandins and cAMP in infected macrophages
- The cPLA2α/COX-1/prostaglandin/cAMP pathway controls immune gene regulation
- MAPKs (ERK, p38) and CREB work together to regulate early immune genes
- NR4A2 is part of a conserved inflammatory response pathway
- This pathway may influence immune function in NR4A2-related conditions
Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease.
Oh SM, Chang MY, Song JJ, Rhee YH, Joe EH, Lee HS, Yi SH, Lee SH
Nurr1 and Foxa2 work together to maintain dopamine-producing neurons, and boosting both proteins may help treat Parkinson's disease by protecting and restoring these critical brain cells.
- Nurr1 and Foxa2 are essential for dopamine neuron health
- Activating both proteins protects neurons in Parkinson's models
- Combined therapy may be more effective than targeting one alone
- This approach could lead to new treatments for Parkinson's disease
Identification of upstream regulators for synovial expression signature genes in osteoarthritis.
Fei Q, Lin J, Meng H, Wang B, Yang Y, Wang Q, Su N, Li J, Li D
This study identifies key transcription factors involved in osteoarthritis, including NR4A2, that regulate genes linked to joint degeneration. The findings suggest potential new targets for treating osteoarthritis by focusing on these regulatory pathways.
- NR4A2 is among top regulators in osteoarthritis joint tissue
- The study links NR4A2 to genes involved in joint breakdown
- Identified transcription factors may lead to new osteoarthritis treatments
- Findings are based on human synovial tissue data from multiple studies
Chiral Dihydrobenzofuran Acids Show Potent Retinoid X Receptor-Nuclear Receptor Related 1 Protein Dimer Activation.
Sundén H, Schäfer A, Scheepstra M, Leysen S, Malo M, Ma JN, Burstein ES, Ottmann C, Brunsveld L, Olsson R
A new compound called 9a activates Nurr1 by binding to RXR, showing strong activity in cells and a precise fit in the receptor's binding site, which may help treat neurodegenerative conditions linked to NR4A2/Nurr1 dysfunction.
- Compound 9a activates Nurr1 via RXR dimerization
- It shows high potency and specificity in cellular tests
- The structure fits perfectly into RXR's binding pocket
- This could lead to new treatments for NR4A2-related disorders
- Enantiomer 9a is the most effective form
Directed Differentiation of Dopamine-Secreting Cells from Nurr1/GPX1 Expressing Murine Embryonic Stem Cells Cultured on Matrigel-Coated PCL Scaffolds.
Terraf P, Babaloo H, Kouhsari SM
This study developed mouse stem cells that produce Nurr1 and a protective enzyme, which were grown into dopamine-secreting neurons using a special 3D scaffold. The resulting neurons functioned well, releasing dopamine when stimulated, showing promise for future Parkinson’s cell therapies.
- Stem cells were engineered to make Nurr1 and a protective enzyme
- Neurons grown on a 3D scaffold produced and released dopamine
- The setup supports functional dopamine neuron development
- Findings could help improve cell therapies for Parkinson’s disease
Parkinson's Disease, Diabetes and Cognitive Impairment.
Ashraghi MR, Pagano G, Polychronis S, Niccolini F, Politis M
Drugs used to treat diabetes, including GLP-1 agonists and metformin, show potential in improving Parkinson's symptoms and cognitive decline, likely by targeting shared brain pathways like insulin resistance and mitochondrial dysfunction. New patents focus on brain-targeted treatments that may help protect neurons in Parkinson's.
- Diabetes drugs like GLP-1 agonists help Parkinson's in studies
- Shared brain issues link diabetes, Parkinson's, and memory loss
- New patents target key proteins like Nurr1 and PINK1
- Better brain drug delivery could boost treatment effectiveness
[Pathological mechanism of secondary-progressive multiples sclerosis and its animal model].
Oki S
In secondary-progressive multiple sclerosis, a harmful type of CD4+ T cell that produces granzyme B and expresses Eomesodermin drives neurodegeneration and chronic inflammation. These cells are found in patients with progressive MS but not in those with relapsing-remitting MS, and blocking Eomes reduces disease severity in a mouse model. This suggests a potential treatment target for slowing or stopping progression in progressive MS.
- Eomes+ CD4+ T cells cause neurodegeneration in progressive MS
- These cells release granzyme B, triggering brain inflammation
- Blocking Eomes reduces disease severity in animal models
- Eomes+ cells are found only in progressive MS patients
- Granzyme B and protease-activated receptor-1 are key in damage
Neuroprotective Transcription Factors in Animal Models of Parkinson Disease.
Blaudin de Thé FX, Rekaik H, Prochiantz A, Fuchs J, Joshi RL
Transcription factors like Nurr1 help protect dopamine-producing brain cells in animals, and studying how they work may lead to new treatments for Parkinson's disease. Disrupting these factors causes symptoms similar to Parkinson's, revealing key pathways involved in neuron survival.
- Nurr1 and other transcription factors protect brain dopamine neurons
- Animal models show Parkinson's-like neuron loss when these factors are disrupted
- Understanding their protective mechanisms could lead to new therapies
- Protein delivery methods may help apply these findings clinically
Effects of RXR Agonists on Cell Proliferation/Apoptosis and ACTH Secretion/Pomc Expression.
Saito-Hakoda A, Uruno A, Yokoyama A, Shimizu K, Parvin R, Kudo M, Saito-Ito T, Sato I, Kogure N, Suzuki D, Shimada H, Yoshikawa T, Fujiwara I, Kagechika H, Iwasaki Y, Kure S, Ito S, Sugawara A
RXR agonist HX630 reduces tumor growth and ACTH production in cells and mice with Cushing's disease by turning off the gene that makes ACTH and triggering cancer cell death. It works by blocking key proteins, including Nurr1, that control ACTH production.
- HX630 reduces ACTH and Pomc gene expression
- HX630 kills corticotroph tumor cells and stops their growth
- HX630 works through RXRα and suppresses Nurr1
- Effect seen in both cells and live mice
- Potential new treatment for Cushing's disease
Role of Nurr1 in the Generation and Differentiation of Dopaminergic Neurons from Stem Cells.
Rodríguez-Traver E, Solís O, Díaz-Guerra E, Ortiz Ó, Vergaño-Vera E, Méndez-Gómez HR, García-Sanz P, Moratalla R, Vicario-Abejón C
Nurr1 is a key protein that helps turn stem cells into dopamine-producing neurons, which can survive and improve movement in animal models of Parkinson's disease. Using Nurr1 with other factors can generate these neurons from stem cells or even reprogram other cells, offering promising paths for studying Parkinson's and developing treatments.
- Nurr1 drives stem cells to become dopamine neurons
- Transplanted Nurr1-engineered neurons improve motor function
- GDNF boosts survival of these transplanted neurons
- This approach works with iPSCs and direct cell reprogramming
- Potential for modeling Parkinson's and testing new therapies
Hnrnph1 Is A Quantitative Trait Gene for Methamphetamine Sensitivity.
Yazdani N, Parker CC, Shen Y, Reed ER, Guido MA, Kole LA, Kirkpatrick SL, Lim JE, Sokoloff G, Cheng R, Johnson WE, Palmer AA, Bryant CD
Hnrnph1 is a gene that influences how sensitive mice are to methamphetamine, a drug that affects the brain's reward system. This gene affects the expression of Nr4a2, a key gene for dopamine neuron development, which may help explain differences in drug response and could inform treatments for addiction and related brain disorders.
- Hnrnph1 affects methamphetamine sensitivity in mice
- Hnrnph1 reduces Nr4a2 expression in the brain
- Lower Nr4a2 levels link to altered dopamine signaling
- This gene may influence addiction and psychiatric conditions
- Findings could guide future therapies for brain disorders
Cell cycle and p53 gate the direct conversion of human fibroblasts to dopaminergic neurons.
Jiang H, Xu Z, Zhong P, Ren Y, Liang G, Schilling HA, Hu Z, Zhang Y, Wang X, Chen S, Yan Z, Feng J
Blocking p53 and halting the cell cycle in human skin cells boosts their conversion into dopamine-producing brain cells, a process that relies on the Tet1 enzyme and could help create personalized cells for Parkinson's research and treatment.
- Stopping p53 and cell division greatly improves conversion of skin cells to dopamine neurons
- The Tet1 enzyme is essential for this reprogramming process
- Resulting neurons act like real midbrain dopamine cells
- This method could generate patient-specific cells for Parkinson's studies
- Overcoming natural barriers may improve cell reprogramming efficiency
Selective early expression of the orphan nuclear receptor Nr4a2 identifies the claustrum homolog in the avian mesopallium: Impact on sauropsidian/mammalian pallium comparisons.
Puelles L, Ayad A, Alonso A, Sandoval JE, MartÍnez-de-la-Torre M, Medina L, Ferran JL
The study finds that a key brain development gene, NR4A2, marks a specific brain region in chickens that is similar to the claustrum in mammals, suggesting a shared evolutionary origin for parts of the brain across species. This helps clarify how brain structures evolved and may inform understanding of NR4A2-related brain development in humans.
- NR4A2 marks a brain region in chickens similar to the mammalian claustrum
- This region develops early and is located in the same brain area as in mice
- The findings support a shared evolutionary origin of certain brain areas
- The deep part of this region may be related to the insula
- This helps explain brain structure evolution across species
Coalition of Nuclear Receptors in the Nervous System.
Förthmann B, Aletta JM, Lee YW, Terranova C, Birkaya B, Stachowiak EK, Stachowiak MK, Claus P
This paper explores how FGFR1, when inside the nucleus, works with other proteins to guide the development of nerve cells, including those that produce dopamine. It highlights a specific interaction between FGFR1 and Nurr1, a protein linked to NR4A2-related disorders, suggesting a potential pathway for understanding or treating neurological symptoms.
- FGFR1 in the nucleus helps control nerve cell development
- FGFR1 works with Nurr1 to form dopamine-producing neurons
- This interaction may explain some neurological features in NR4A2 disorders
- The findings point to possible new treatment targets
Zdhhc15b Regulates Differentiation of Diencephalic Dopaminergic Neurons in zebrafish.
Wang F, Chen X, Shi W, Yao L, Gao M, Yang Y, Hao A
Zdhhc15b is essential for the development of dopamine-producing neurons in zebrafish, particularly in the brain region that may relate to human dopaminergic disorders. Reducing Zdhhc15b function leads to fewer mature dopamine neurons and impaired learning, likely by disrupting key genes that guide neuron identity.
- Zdhhc15b helps form dopamine neurons in zebrafish brain
- Lower Zdhhc15b reduces mature dopamine neurons and learning ability
- It affects neuron identity, not survival or growth of precursor cells
- Zdhhc15b works through genes like Nurr1 involved in dopamine neuron development
- Zebrafish model links Zdhhc15b to dopamine neuron formation
Understanding gene expression in coronary artery disease through global profiling, network analysis and independent validation of key candidate genes.
Arvind P, Jayashree S, Jambunathan S, Nair J, Kakkar VV
This study identified genes linked to coronary artery disease (CAD) using blood gene expression data from Indian adults, finding that inflammation and immune-related genes, including NR4A2, are highly active in CAD patients. The results suggest these genes play a key role in disease development and could be targets for future treatments.
- NR4A2 is upregulated in CAD patients
- Inflammation and immune genes are central to CAD
- Findings were confirmed in a larger group of patients
- NR4A2 may contribute to disease progression
- Results point to potential treatment targets
Elevated α-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cells.
Oliveira LM, Falomir-Lockhart LJ, Botelho MG, Lin KH, Wales P, Koch JC, Gerhardt E, Taschenberger H, Outeiro TF, Lingor P, Schüle B, Arndt-Jovin DJ, Jovin TM
Overexpression of alpha-synuclein due to a SNCA gene triplication impairs the ability of neural stem cells to develop into mature neurons, particularly dopamine and GABA-producing neurons, which may contribute to Parkinson's disease progression and affect brain repair mechanisms.
- Alpha-synuclein overexpression disrupts neuron development
- Fewer dopamine and GABA neurons form in patient cells
- Neuronal maturation is delayed and less active
- Key genes for neuron function are reduced
- Increased stress response suggests cellular strain
Intergenerational Effect of Early Life Exposure to Permethrin: Changes in Global DNA Methylation and in Nurr1 Gene Expression.
Bordoni L, Nasuti C, Mirto M, Caradonna F, Gabbianelli R
Exposure to the pesticide permethrin in early life can cause lasting changes in DNA methylation and reduce Nurr1 gene expression, which are passed to offspring even without direct exposure. These changes mirror those seen in Parkinson’s disease and suggest a potential intergenerational risk for neurodevelopmental and neurodegenerative conditions.
- Permethrin exposure alters DNA methylation and Nurr1 expression
- These changes are passed to offspring without direct exposure
- Nurr1 is linked to Parkinson’s and brain development
- Findings suggest intergenerational neurotoxic risk
- May inform future prevention or early intervention
Optogenetic Inhibitor of the Transcription Factor CREB.
Ali AM, Reis JM, Xia Y, Rashid AJ, Mercaldo V, Walters BJ, Brechun KE, Borisenko V, Josselyn SA, Karanicolas J, Woolley GA
This study developed a light-controlled system to inhibit the transcription factor CREB, which regulates genes like NR4A2. The tool allows precise, real-time control of gene expression in cells and neurons, offering a way to study how CREB and NR4A2 work together in brain function.
- A light-switchable inhibitor of CREB was created.
- It controls expression of NR4A2 and other key genes.
- The system works in neurons and could model brain-related gene regulation.
- This approach may help study NR4A2-related disorders.
- It enables precise timing and location of gene control.
Development and function of the midbrain dopamine system: what we know and what we need to.
Bissonette GB, Roesch MR
This review explains how midbrain dopamine neurons form during development and how disruptions in this process may contribute to disorders like Parkinson's, autism, and schizophrenia. It highlights key genes and molecules involved in dopamine neuron development and their links to behavior and disease.
- Dopamine neuron development is crucial for brain function and behavior
- Disruptions in development may lead to Parkinson's, autism, and schizophrenia
- Key genes and molecules guide dopamine neuron formation
- Understanding development may reveal new treatment paths
- Research bridges developmental and behavioral neuroscience
Contra-directional Coupling of Nur77 and Nurr1 in Neurodegeneration: A Novel Mechanism for Memantine-Induced Anti-inflammation and Anti-mitochondrial Impairment.
Wei X, Gao H, Zou J, Liu X, Chen D, Liao J, Xu Y, Ma L, Tang B, Zhang Z, Cai X, Jin K, Xia Y, Wang Q
Memantine protects brain cells in a lab model of Parkinson's disease by reducing harmful Nur77 activity and boosting protective Nurr1 signaling, suggesting a potential treatment strategy for NR4A2-related disorders involving mitochondrial damage and inflammation.
- Memantine reduces harmful Nur77 activity in brain cells
- Memantine boosts protective Nurr1 signaling
- Nur77 and Nurr1 work in opposite ways during neurodegeneration
- This balance may be key in protecting neurons
- Findings suggest memantine could help in NR4A2-related conditions
Nurr1 and Retinoid X Receptor Ligands Stimulate Ret Signaling in Dopamine Neurons and Can Alleviate α-Synuclein Disrupted Gene Expression.
Volakakis N, Tiklova K, Decressac M, Papathanou M, Mattsson B, Gillberg L, Nobre A, Björklund A, Perlmann T
This study found that alpha-synuclein disrupts gene expression in dopamine neurons by interfering with the Nurr1 transcription factor, which is critical for neuron health. Drugs that activate Nurr1’s partner receptor (RXR), like bexarotene, can restore key signaling pathways, including Ret, which supports neuron survival. While bexarotene did not protect neurons in rats, the results suggest other RXR-targeting drugs may help treat Parkinson’s disease.
- Alpha-synuclein harms dopamine neurons by disrupting Nurr1 function
- Nurr1 controls genes essential for neuron survival and function
- RXR ligands like bexarotene can restore Ret signaling in affected neurons
- Other RXR drugs may have therapeutic potential for Parkinson’s
- Nurr1 pathway is a promising target for future treatments
Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.
Alvarsson A, Zhang X, Stan TL, Schintu N, Kadkhodaei B, Millan MJ, Perlmann T, Svenningsson P
TAAR1 appears to worsen dopamine neuron loss and increase sensitivity to L-DOPA side effects like dyskinesia, while activating TAAR1 may reduce these issues by calming overactive glutamate signaling in the brain. This suggests TAAR1 could be a target for treating Parkinson’s disease symptoms and side effects.
- TAAR1 activation reduces L-DOPA-induced dyskinesia
- TAAR1 modulates glutamate release in the striatum
- TAAR1 loss worsens L-DOPA sensitivity
- TAAR1 agonists may protect dopamine neurons
- TAAR1 affects both dopamine and glutamate systems
Dissecting the role of Engrailed in adult dopaminergic neurons--Insights into Parkinson disease pathogenesis.
Rekaik H, Blaudin de Thé FX, Prochiantz A, Fuchs J, Joshi RL
Engrailed proteins help protect dopamine neurons in the adult brain, and their loss leads to Parkinson's-like symptoms and neuron death in mice, suggesting a key role in preventing Parkinson's disease. This protection involves supporting mitochondrial function, which is relevant to understanding and treating neurodegenerative conditions like NR4A2-related syndrome.
- Engrailed proteins protect adult dopamine neurons
- Loss of Engrailed causes Parkinson's-like symptoms in mice
- Engrailed supports mitochondrial health in neurons
- Other developmental factors like Nurr1 also maintain neuron survival
- These findings may inform therapies for dopamine neuron disorders
Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation.
Raveney BJ, Oki S, Hohjoh H, Nakamura M, Sato W, Murata M, Yamamura T
Eomesodermin-expressing CD4+ T cells drive chronic neuroinflammation in a mouse model of multiple sclerosis and are also elevated in people with progressive MS, suggesting they contribute to ongoing disease. These cells release granzyme B and activate protease-activated receptor-1, promoting brain inflammation.
- Eomes+ CD4+ T cells cause chronic MS-like disease
- These cells are found in blood and spinal fluid of progressive MS patients
- They release granzyme B and activate inflammatory pathways
- Blocking Eomes reduces disease severity in mice
- Potential new target for treating progressive MS
Noggin Over-Expressing Mouse Embryonic Fibroblasts and MS5 Stromal Cells Enhance Directed Differentiation of Dopaminergic Neurons from Human Embryonic Stem Cells.
Lim MS, Shin MS, Lee SY, Minn YK, Hoh JK, Cho YH, Kim DW, Lee SH, Kim CH, Park CH
Exposing human stem cells to a protein called noggin early in development significantly improves their ability to become dopamine-producing brain cells, which are relevant to NR4A2-related disorders. This method boosts key markers of midbrain dopamine neurons and reduces undifferentiated stem cell presence.
- Early noggin exposure boosts dopamine neuron formation
- Noggin-enhanced stromal cells improve differentiation efficiency
- Key dopamine markers (Nurr1, TH, Girk2) increase
- Undifferentiated stem cell markers decrease
- Potential for improving cell-based therapies
A novel synthetic activator of Nurr1 induces dopaminergic gene expression and protects against 6-hydroxydopamine neurotoxicity in vitro.
Hammond SL, Safe S, Tjalkens RB
C-DIM12, a synthetic compound, activates Nurr1 in dopamine-producing neurons, boosts the expression of genes that protect these neurons, and helps them survive toxic damage in lab studies. This suggests C-DIM12 could potentially support dopamine neuron health in conditions like NR4A2-related syndrome.
- C-DIM12 activates Nurr1 in dopamine neurons
- It increases protective genes linked to Nurr1
- It improves neuron survival after toxin exposure
- Findings are in human-derived neuron models
- Potential for protecting neurons in NR4A2-related disorders